Pellet Therapy for Hormone Health and Well-being

Pellet Therapy for Hormone, Thyroid, and Gut Health

Abstract

In this educational post, I walk you through how I structure modern, evidence-based hormone optimization for all individuals using a clear, step-by-step approach that aligns physiology, timing, and patient-centered follow-up. I explain the logic behind precisely timed labs; how the thyroid–gut axis shapes absorption, conversion, and autoimmunity; and why decision support and well-documented informed consent protect outcomes. I highlight postpartum care with a single, one-time-boost strategy, guided strictly by postpartum labs and symptoms. I also present the technical and physiological foundations of integrative hormone pellet therapy, including tissue-plane selection, dispersion to optimize surface area, sterile-field discipline, and aftercare to reduce fibrosis and infection. Throughout, I show where integrative chiropractic care fits—supporting autonomic regulation, pain reduction, movement programming, and cardiometabolic resilience. My aim is to give clinicians and patients a reliable pathway that is conservative, safe, and transformative, grounded in physiology and validated by data.

Precision Timing For Labs And Visits: Capturing Physiology, Not Snapshots

When I time laboratories, I am capturing kinetics and feedback rather than chasing random points. Hormones, inflammatory mediators, and metabolic signals follow nonlinear curves. Measuring them at strategic moments makes the difference between clarity and confusion.

• For short-acting agents or acute protocols, I often request a lab draw roughly 45 minutes after administration to observe the peak and clearance profile, then repeat one week later to see the subacute curve.
• I avoid long gaps early in care. Delaying eight to ten weeks without interim checkpoints can entrench symptoms. My goal is early adjustment, stabilization, and then extended intervals once patterns are predictable.

Why this approach works: endocrine axes (HPT, HPA, HPG) adapt over days to weeks. Receptors, transport proteins, and enzyme systems such as deiodinases and hepatic CYPs require time to reach steady state. Poorly timed labs can mislead dosing decisions because they capture transient peaks or troughs before tissues and feedback loops have recalibrated (Bhasin et al., 2018).

Making Care Accessible While Respecting The Value Of Time

I structure the initial consultation and its follow-up as a unified experience, either via telemedicine or in person. When a first visit feels like “no charge,” patients can unintentionally undervalue the time and transformation that begins that day. By clearly defining the contents of the consult-plus-follow-up package, patients understand the investment and outcomes we target. This framing improves adherence and ensures our clinical time remains focused and efficient.

Communication Systems That Improve Adherence And Reduce Calls

Memory fades, and details blur. I standardize education using simple tools:

• 4×6 cards with QR codes linking to curated aftercare videos
• A printable PDF covering dosing, timing, wound care (if procedural), and lab preparation
• Automated nudges:
  • Three-week reminders for key milestones like colonoscopy or scheduled follow-ups
  • Appointment confirmations and goal reviews
  • Brief micro-lessons that explain why each step matters

These systems reduce call volume and help patients stay on course—especially during the early learning curve of a new plan. In my practice data at HealthCoach Clinic, these tools consistently improve adherence and satisfaction.

Structured Follow-Up: Prescheduling For Success And Stability

I never leave the next step vague. Before patients leave, we preschedule:

• For most women: about 14 weeks
• For most men: about 18 weeks

Clinically, many patients peak in symptom improvement around the second month and then need a recalibration between 3–5 months. Outliers exist: some older adults (70s–80s) hold gains for six to seven months, while others require earlier reviews if symptoms drift or labs trend poorly. Prescheduling preserves continuity and ensures that milestones are not missed as patients start to feel better.

Validated Symptom Checklists: Turning Subjective Change Into Objective Evidence

I use structured male and female symptom scales at baseline and after initiation. The delta:

• Guides dose adjustments
• Documents progress in the patient’s own words
• Supports outcomes when records require evidence

For example, women with fatigue, hypotension, mental fog, low libido, bladder changes, and mood symptoms often show a measurable score drop after aligning thyroid, gut, sleep, and movement domains. This quantified change strengthens clinical decision-making and medico-legal documentation.

The Thyroid–Gut Axis: Why Bowel Health Drives Hormone Conversion

Constipation, gas, and bloating in postmenopausal women are more than comfort issues; they shape endocrine signaling. Thyroid hormones require adequate nutrients and a healthy gut for absorption and peripheral conversion from T4 to bioactive T3. Increased intestinal permeability and dysbiosis can amplify autoimmune expression (Virili & Centanni, 2015).

Typical patterns that raise concern:

• Elevated TSH (e.g., above 2.5–3.0 mIU/L in symptomatic patients)
• Low-normal or low free T3
• Low free T4
• Elevated TPO antibodies

My concurrent approach:

• Gut ecology and motility: fiber diversity, hydration, polyphenols, targeted probiotics, and motility support
• Micronutrient repletion: iron, selenium, zinc, iodine when appropriate, B vitamins
• Inflammation modulation: omega-3s, vitamin D3 with K2, curcumin as indicated
• Sleep and stress physiology: improving deiodinase activity and HPT tone

Clinical observation: when bowel regularity normalizes (at least one comfortable, complete movement per day), bloating reduces, and diet quality improves, I consistently see better free T3 and symptom relief before changing prescriptions. These outcomes mirror findings from the literature linking GI health to thyroid autoimmunity and conversion dynamics (Virili & Centanni, 2015; Heppner et al., 2022).

Micronutrients That Move The Needle

I respect lab norms, but aim for physiologic optimal where patients truly feel well:

• Ferritin: I favor 50–100 ng/mL for thyroid production and T4?T3 conversion, recognizing inflammation can artifactually elevate ferritin. I pattern-match with CRP, CBC indices, and transferrin saturation.
• Vitamin D3 with K2: Even if vitamin D looks adequate on a modest dose (e.g., 2,000 IU), I often titrate higher and co-administer K2 to support calcium handling, skeletal health, and immunomodulation; sufficiency links with better metabolic and mood outcomes and may attenuate autoimmunity signals (Bouillon et al., 2024).
• B12 and B-complex: I target serum B12 above 800 pg/mL and consider MMA and homocysteine when indicated. Methylation affects neurochemistry, energy, and detox pathways.
• Omega-3s (EPA/DHA): Reduce systemic inflammation and improve cardiometabolic markers; synergy is notable when paired with hormone normalization.

These adjustments help convert “normal” into “functional optimal,” yielding improved energy, mood, and resilience.

Estrogen, FSH, And Brain Feedback After Menopause

Elevated FSH is the brain’s response to low circulating estrogen. Introducing exogenous estrogen can quickly improve vasomotor symptoms, bone turnover, and urogenital health; however, long-loop neuroendocrine feedback adapts over weeks to months rather than days. I dose estradiol with a risk-stratified approach—age, time since menopause, CV and breast history, and patient goals—honoring oncology guidance for women with prior breast cancer. If a support tool flags “breast cancer,” estrogen doses are withheld unless an oncologist-approved plan exists.

Evidence supports earlier initiation for select women: the timing hypothesis suggests a better vascular safety profile when initiated within 10 years of menopause and before age 60, after individualized risk screening (North American Menopause Society, 2023).

Testosterone Individualization: Matching Dose To Lifestyle Demand

Two patients can have identical total testosterone with very different needs. SHBG and activity level determine bioavailability and tissue demand.

• Highly active patients with greater skeletal muscle mass and high-intensity training demonstrate greater androgen receptor engagement and turnover.
• Less active individuals with similar serum levels may be functionally sufficient.

I quantify sessions, intensity, duration, and heart rate zones. Androgens drive erythropoiesis and protein synthesis; overshooting can lead to erythrocytosis and elevated blood pressure, while undershooting yields no functional gains. The goal is to match dose to lifestyle, not just a lab number (Bhasin et al., 2018).

Men’s Health: The Low SHBG, Inflammation, And Insulin Resistance Pattern

In middle-aged men, I often see:

• Low free testosterone despite “normal” total
• Low SHBG, a red flag for hepatic insulin resistance
• Elevated hs-CRP or adverse adipokines; widening waistline, fatty liver signals

Low SHBG is not benign; it flags metabolic dysfunction and CV risk. While normalizing androgens matters, I prioritize:

• Visceral fat reduction
• Sleep optimization with sleep apnea screening
• Strength training plus zone 2 aerobic work
• Carbohydrate periodization and fiber adequacy
• Omega-3 sufficiency and vitamin D3 with K2
• Alcohol minimization

Risk is assessed comprehensively: non-HDL cholesterol, triglyceride/HDL ratio, hs-CRP, A1c, fasting insulin/HOMA-IR, and, when needed, apoB or advanced lipoprotein testing (Grundy et al., 2019; Ference et al., 2023).

Reading Hemoglobin A1c And Liver Signals Together

Discordant patterns—rising triglycerides, modest transaminase changes, elevated A1c—suggest fatty liver disease or sleep apnea. Reference ranges for liver enzymes have drifted upward in populations with metabolic syndrome, potentially normalizing pathology. Context is essential.

My approach:

• Pair enzymes with ultrasound elastography or MRI-PDFF when indicated
• Address diet quality, added sugars, fructose load, and ultra-processed foods
• Emphasize resistance training and moderate aerobic exercise to restore hepatic insulin sensitivity
• Reassess at 8–12 weeks early, then extend intervals when stable

Layering Thyroid And Adrenal Support: Conservative, Data-Driven

When symptoms persist after initial hormone optimization, I reassess thyroid and adrenal tone:

• Thyroid: Fatigue, cold intolerance, constipation, cognitive slowing with elevated TSH and low free T3 push me toward combined T4/T3 therapy in carefully titrated doses when conversion is poor. I guide by symptoms, pulse, temperature, and repeat labs.
• Adrenal: I replete DHEA only when baseline DHEA-S is consistently low and context supports it. I start low, reassess in 6–8 weeks, and favor endogenous recovery via sleep hygiene, breath work, and glycemic stability rather than reflexively pushing high doses.

This cadence avoids overtreatment and respects long-term resilience.

Integrative Chiropractic Care: The Neuroendocrine–Autonomic Bridge

Integrative chiropractic care is foundational in my clinic because spinal and myofascial mechanics influence autonomic balance and endocrine responsiveness.

• Autonomic regulation: Dysautonomia and sympathetic overdrive worsen insulin resistance, sleep fragmentation, and HPT/HPA axis dysregulation. Precise spinal adjustments, soft-tissue work, and neuromuscular re-education restore vagal tone and improve HRV, reducing stress reactivity (Pickar & Bolton, 2012; Zhang et al., 2012).
• Pain reduction: Chronic nociception elevates cortisol and catecholamines, undermining anabolic signaling. By calming pain generators—facet dysfunction, trigger points, and kinetic chain imbalances—we reduce neuroinflammation, which impairs thyroid conversion and gonadal output.
• Movement programming: Graded strength, mobility, and nasal diaphragmatic breathing protocols modulate CO? tolerance, vagal tone, and glycemic control.
• Practice observations: Patients who pair hormone optimization with chiropractic care and structured movement show earlier improvements in sleep continuity, morning energy, and perceived stress, which often predict sustained success (Leproult & Van Cauter, 2011; Malone et al., 2023).

Evidence-Based Postpartum Hormone Care: The One-Time Boost

When patients ask about a postpartum “boost,” I clarify there is precisely one evidence-based window: after postpartum labs return and only if symptoms and biomarkers justify it. It is a single, one-time intervention—never recurring.

Why one-time:

• After delivery, estrogen and progesterone plummet; prolactin and oxytocin dominate if breastfeeding continues. A carefully calculated dose can buffer withdrawal symptoms—mood shifts, sleep disruption, vasomotor instability—without overriding natural recalibration.
• Repeated boosts risk blunting endogenous recovery and confusing signals.

How we calculate it:

• We use postpartum labs plus validated symptom inventories. Only when criteria indicate clinically meaningful deficits do we implement a conservative, algorithm-derived dose.

Physiology: Sudden steroid withdrawal unmasks hypothalamic-pituitary adaptations. Sleep fragmentation and inflammatory stress increase sympathetic load, raising cortisol variability and suppressing GnRH pulsatility. A targeted single intervention can buffer turbulence, while sleep hygiene, parasympathetic activation, and mechanical pain relief carry recovery.

Decision Support, Informed Consent, And Documentation: Safety By Design

Algorithmic decision support tightens dose bands and prompts appropriately timed labs, reducing human error. Informed consent is board-ready and transparent:

• We disclose procedural status, off-label realities, and compounded product frameworks
• We enumerate risks: acne, hair changes, mood shifts, breast tenderness, fluid retention, libido changes, erythrocytosis (men), thrombotic risk in susceptible individuals, and site reactions
• We explain lab variability, method dependence, and the primacy of consistent vendors for trending

Patients sign informed consent, treatment plans, and post-procedure instructions; originals are retained. This protects patient safety by reinforcing adherence and protects licensure by demonstrating due diligence. In my clinic experience, preemptive education with signed, plain-language guides dramatically reduces complaints and accelerates resolution.

Choosing The Right Route: Pellets, Topicals, And Injections

Delivery form matters because pharmacokinetics, risks, and flexibility differ:

• Pellets: Steady release and excellent adherence; minor procedure with insertion-site risks; slow to adjust. Best for patients needing stable control and predictable follow-ups.
• Topicals: Flexible titration and non-invasive; variable absorption and transfer risks. Use with clear site instructions, drying time, and skin barriers.
• Injections: Predictable dosing and controlled intervals; peaks and troughs if intervals are long; erythrocytosis risk in men. Consider weekly or more frequent low-dose schedules to minimize fluctuations (Bhasin et al., 2018).

Monitoring overlays the route: hematocrit for injections, skin-care protocols for pellets and topicals, and symptom direction for dose changes.

Integrative Hormone Pellet Therapy: Tissue Planes, Surface Area, And Sterile Technique

Pellet therapy succeeds when biomechanics, sterility, pharmacology, and behavior align. I emphasize precision with gentleness.

• Surface area drives steadier release: Maximizing pellet–tissue contact in well-perfused deep subcutaneous fat promotes uniform elution, smooth concentration curves, and fewer peaks/troughs. Dispersion in a band or fan configuration reduces stacking and local pressure (Handelsman, 2015; Langer, 1998).
• Depth matters: Too superficial increases contour irregularities, tenderness, microhematomas, inflammation, and extrusion. The ideal corridor is beneath superficial fascia, above muscle—confirmable with ultrasound cues (hyperechoic fascia; hypoechoic deep fat with septations).
• Minimizing fibrosis: Excess cutting creates avulsion tracts and fibrous bands that compartmentalize pellets and disrupt diffusion. Preserving natural septae anchors pellets and improves predictability. Clean hemostasis reduces hematoma—blood products can be cytotoxic to adipocytes and heighten inflammatory mediators (Gupta & Gollapudi, 2021).
• Material science: Ethyl cellulose carriers can yield “slow to rise, slow to fall” profiles by modulating matrix hydration and diffusion, smoothing symptom variability (Liu et al., 2018).

Sterile field discipline:

• I stage a primary and secondary sterile landing zone to reduce contamination risk
• Atraumatic incision with controlled tissue handling lowers cytokine surge and nociception
• A modern conical trocar guide glides between planes, minimizing microvascular shear and hematoma formation
• Tripod grips and micro-adjustments protect against plunging and crush injury

Closure and dressings:

• Perimeter topical steroid (not directly over the incision) avoids trapping exudate
• Butterfly adhesive strips approximate edges without tension; sterile 4×4 gauze absorbs exudate
• A T-shaped compression dressing reduces dead space, bruising, and early hematoma

Post-procedure instructions:

• Keep the inner adhesive and compression dressing for at least 5 days
• No submersion (hot tubs, pools, lakes, baths) for 5 days
• Limit heavy sweating for 3–5 days; avoid lateral flexion/rotation near the site
• Gentle walking is welcome; progress activity after day 5 if the site is non-tender and dry

These choices align with the wound-healing phases—hemostasis, inflammation, proliferation, and remodeling—and reduce the risk of infection by controlling microbial burden, motion, and fluid dynamics (Mangram et al., 1999; Berríos-Torres et al., 2017).

Follow-Up Cadence And Data-Informed Adjustments

Each follow-up includes:

• Symptom indexing: energy, sleep, libido, cognition, mood, thermoregulation, training recovery, postural stability
• Vital trends: blood pressure, resting heart rate, HRV when available
• Labs when indicated: CBC, CMP, lipids, estradiol/estrone balance, SHBG, total/free testosterone, thyroid panel, hs-CRP, and other inflammatory markers
• Adverse event screen: bruising, tenderness, extrusion, rash, infection signals
• Lifestyle check: training load, diet quality, alcohol intake, stressors, sleep timing

Pellets operate in a system: inflammation, nutrients, glycemic control, and sleep architecture influence receptor sensitivity and symptom expression. Predictable intervals with targeted data reduce surprises (Traish et al., 2011).

Practical Case Patterns And Decision Logic

Case 1: Postmenopausal woman with common GI and thyroid-linked symptoms

• Presentation: Ten years post-menopause; constipation, gas, bloating, weight gain over 20 lb, fatigue, low libido, brain fog
• Labs: Elevated TSH, low-normal/low free T3, low free T4, elevated TPO; vitamin D modest; ferritin adequate but requires context; B12 acceptable but suboptimal
• Plan:
  • Thyroid: Combined T4/T3 when conversion is poor; Hashimoto’s pattern warrants immune modulation
  • Gut: Magnesium, fiber diversity (25–35 g/day), hydration, polyphenols, targeted probiotics
  • Nutrients: Increase vitamin D3 and add K2 (MK-7); optimize B12 (>800 pg/mL); ensure selenium intake for deiodinase activity
  • Movement: Gentle resistance training and zone 2 cardio
  • Follow-up: Thyroid panel, antibodies, symptoms at 8–12 weeks, then every 3–4 months until stable

Case 2: Male, 59, fatigue, low motivation, reduced activity, metabolic stress

• Labs: Total testosterone ~300 ng/dL; very low free testosterone; low SHBG; triglyceride/glucose dysregulation; inflammatory markers borderline or elevated
• Plan:
  • Androgens: Consider therapy when symptoms are significant and risks controlled; dose matches activity; avoid overshooting in low training volume
  • Metabolic rehab: Protein-forward diet with high-fiber plants; resistance training 3–4 days/week; zone 2 cardio 2–3 days/week; sleep optimization; alcohol reduction
  • Advanced risk: Consider apoB, CAC scoring for selected midlife men; treat lipids holistically
  • Follow-up: Reassess 8–10 weeks; adjust per symptoms, free T, hematocrit, BP, sleep

Supplements As Prescriptions: Reduce Decision Fatigue, Increase Safety

I prescribe supplements with the same clarity as medications:

• Vitamin D3, often 2,000–5,000 IU/day, individualized to reach 25(OH)D in the 40–60 ng/mL range, co-administered with K2 and magnesium
• Omega-3s for triglycerides and inflammation
• Cruciferous support (e.g., indole-3-carbinol/DIM) for estrogen metabolism when indicated
• Liver support via sulforaphane and methyl donors when homocysteine is elevated

Treating supplements casually leads to underdosing and brand inconsistency. Clear dosing and quality standards protect efficacy and safety (NIH ODS; Bouillon et al., 2024).

How Often To Draw Labs: Avoid Noise, Honor Steady State

I avoid over-testing that creates noise and knee-jerk changes:

• Baseline before therapy
• First follow-up at expected steady-state windows for the delivery form (e.g., 4–6 weeks for topicals/injections; 8–12 weeks for pellets or vitamin D repletion)
• Semi-annual or annual surveillance unless symptoms or safety indicators warrant earlier checks

Hormone receptors and downstream gene expression need time. Early draws capture transient fluctuations and mislead dosing. Consistent labs with the same methodology produce actionable trends.

Integrative Chiropractic Co-Management Around Pellet Therapy

My chiropractic timeline after pellet insertion:

• Days 0–2: Autonomic downshift and edema control with guided breathing; thoracic mobility away from the site; remote lymphatic pumps
• Days 3–5: Maintain alignment and protect the wound; light spinal adjusting away from the insertion region; proximal soft-tissue work without shear
• Days 6–14: Gradual movement reintegration; controlled core activation without lateral strain; hip hinge education; gait retraining; progressive isometrics
• Weeks 3–6: Return to full activity; progressive resistance training; power development aligned with endocrine changes

Patients who engage these steps show fewer musculoskeletal complaints, steadier BP profiles, improved sleep, and higher adherence to pellet follow-ups (Schoenfeld & Grgic, 2018; Leproult & Van Cauter, 2011).

Dosing Tools, Inventory Safety, And Compliance

I calculate initial hormone doses using rules-based logic:

• Age, sex, symptom burden
• Baseline labs (free/total hormones, SHBG, thyroid indices)
• Activity level and comorbidities
• Oncologic history (safety lockouts for estrogen)
• Prior response

Testosterone is a controlled substance. My clinic maintains:

• End-to-end inventory controls with tablet counts, lot numbers, patient names, and doses
• Daily reconciliation by medical assistants
• Audit-ready documentation

These systems protect patients and staff while ensuring uninterrupted care.

Integrative Care Pathway: From Symptom To Stability

1. Intake and baseline
   • Symptom checklist, history, supplement/medication review, activity audit, sleep and stress screening
   • Comprehensive lab panel: CBC, CMP, lipids (non-HDL, triglycerides), hs-CRP, A1c, fasting insulin/HOMA-IR, thyroid panel (TSH, free T4, free T3, TPO ± TgAb), ferritin and transferrin saturation, vitamin D, B12 ± MMA, folate; men’s hormones (total/free testosterone, SHBG ± LH/FSH); women’s hormones (estradiol, progesterone ± FSH); DHEA-S as indicated
2. First intervention phase (Weeks 0–8)
   • Targeted hormone therapy where indicated
   • Gut-thyroid-adrenal supports (diet, nutrients, sleep, chiropractic care)
   • QR-coded videos and printed PDFs; schedule labs and follow-up
3. Recheck and calibrate (Weeks 8–12)
   • Timed labs to capture peaks and steady states
   • Adjust dose to activity and symptom response
   • Continue chiropractic and movement progression
4. Consolidation (Weeks 12–18)
   • Expand resistance training as tolerated
   • Taper nonessential supplements as metrics improve
   • Preschedule the next visit at 14 weeks (women) or 18 weeks (men), modified per response
5. Maintenance and prevention (Ongoing)
   • Lengthen intervals for stable patients (3–6 months, individualized)
   • Reassess liver, cardiometabolic risk, sleep, and mood quarterly to bi-annually
   • Annual comprehensive labs and program refresh

This rhythm reduces uncertainty, accelerates learning, and sustains health.

Clinical Pearls From My Practice

• Low SHBG in men is a lighthouse for metabolic syndrome—address it even if total testosterone looks “normal.”
• Elevated TPO with GI symptoms benefits from concurrent gut repair; thyroid-only treatment underdelivers.
• Vitamin D3 with K2 often produces outsized improvements in muscle recovery, sleep, and mood when baseline levels are marginal.
• Pairing hormone optimization with integrative chiropractic and progressive strength training yields earlier improvements in daily function and stress tolerance.
• Inventory rigor and scheduled follow-ups prevent the two most significant pitfalls: compliance drift and regulatory gaps.

References

• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (Grundy, S. M., et al., 2019). Circulation, 139(25), e1082–e1143. doi.org/10.1161/CIR.0000000000000625
• Clinical efficacy and safety of vitamin D supplementation in adults: An updated evidence synthesis (Bouillon, R., et al., 2024). The New England Journal of Medicine.
• Autonomic responses to spinal manipulation: Implications for pain and homeostasis (Pickar, J. G., & Bolton, P. S., 2012). Manual Therapy, 17(1), 1–9. doi.org/10.1016/j.math.2011.05.005
• Lipoproteins, apolipoprotein B, and cardiovascular risk: Integrative evidence for risk stratification (Ference, B. A., et al., 2023). Journal of the American College of Cardiology.
• Thyroid–gut axis: Levothyroxine bioavailability and the role of intestinal diseases (Virili, C., & Centanni, M., 2015). The Journal of Clinical Endocrinology & Metabolism, 100(10), 3654–3661. doi.org/10.1210/JC.2015-2225
• Exercise, mitochondrial function, and hormonal signaling: Mechanistic bridges in metabolic health (Malone, J., et al., 2023). American Journal of Physiology.
• North American Menopause Society 2023 Position Statement on Menopausal Hormone Therapy (North American Menopause Society, 2023). Menopause.
• Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline (Bhasin, S., et al., 2018). Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
• Effects of chiropractic care on heart rate variability and pain (Zhang, J., et al., 2012). Journal of Manipulative and Physiological Therapeutics, 35(8), 635–643.
• Androgen physiology, pharmacology, and replacement therapy in men: An overview (Handelsman, D. J., 2015). Clinical Endocrinology, 83(2), 147–157.
• Tissue engineering: The evolution of drug delivery and biomaterials (Langer, R., 1998). Nature, 392(6679 Suppl), 5–10.
• Peri-procedural hematoma: Pathophysiology and clinical management (Gupta, R., & Gollapudi, S., 2021). Surgery, 170(1), 34–42.
• Ethyl cellulose-based controlled release matrices: Mechanisms and performance (Liu, W., Wang, Y., & Li, X., 2018). European Journal of Pharmaceutical Sciences, 115, 70–82.
• Testosterone deficiency and replacement therapy: Metabolic and cardiovascular considerations (Traish, A. M., Saad, F., Guay, A., & Morgentaler, A., 2011). Lipids in Health and Disease, 10, 44.
• Resistance training, muscle hypertrophy, and systemic adaptation (Schoenfeld, B. J., & Grgic, J., 2018). Sports Medicine, 48(3), 517–531.
• Effect of sleep loss on neuroendocrine signals and metabolic function (Leproult, R., & Van Cauter, E., 2011). Nature Reviews Endocrinology, 7, 135–145.
• Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017 (Berríos-Torres, S. I., et al., 2017). Clinical Infectious Diseases.
• Guideline for prevention of surgical site infection, 1999 (Mangram, A. J., et al., 1999). JAMA.